As the population ages the incidence of neurodegenerative diseases is increasing, and with no effect treatments, they represent a major public health problem. Advances in human genetics and the identification of risk genes have allowed the application of modern molecular biological and genomic tools to study disease mechanisms. These studies have revealed the importance of immune mechanisms, RNA metabolism, lysosomal biology and autophagy in disease risk. The 2020 Gordon Conference on Neurobiology of Brain Disorders will bring together leaders in basic, clinical and translational research to discuss their latest findings and novel concepts. Invited speakers represent a wide variety of scientific disciplines including genetics, genomics, systems biology, cell biology, disease modeling in cells and animals, biomarker discovery and therapeutic development. The conference will also provide a platform for junior scientists and graduate students to present their work and to interact informally with leaders in the field.
The conference will consist of nine sessions, on the topics listed below. The conference chair is currently developing their preliminary program, which will include the names of the invited speakers and discussion leaders for each of these sessions. Please check back regularly for updates to this information.
- Keynote Session: Development of ASOs as an FDA Approved Treatment for Neurodegenerative Disease
- Genetic and Genomic Approaches to Neurodegenerative Disease
- Epigenetics of Neurodegenerative Disease
- TDP43 Dysfunction in Frontotemporal Dementia and ALS
- Neuronal and Non-Neuronal Mechanisms in Parkinson's Disease
- Microglia Dysfunction and Synaptic Degeneration in Alzheimer's Disease
- Structural and Functional Studies of Tau, Impact of the Immune System and Genomic Integrity on Tauopathies
- Diagnostic and Theranostic Biomarkers of Neurodegeneration
- Use of Small Molecules and Biologics in the Treatment of Neurodegenerative Disease